Kythera Biopharmaceuticals Receives Notice of Allowance from U.S. Patent Office for Composition Claims Covering ATX-101 Active Ingredient

Published: Jun 01, 2012

LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application that claims synthetic deoxycholic acid or pharmaceutically acceptable salts thereof, including the synthetic form that is used in ATX-101, a potential first-in-class, injectable drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable “double chin.”

Back to news